Jt Stratford LLC Vertex Pharmaceuticals Inc Transaction History

Jt Stratford LLC

$568 Million
Q3 2024

A detailed history of Jt Stratford LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jt Stratford LLC holds 8,898 shares of VRTX stock, worth $4.01 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares

8,898

Previous 8,881 0.19%

Holding current value

$4.01 Million

Previous $4.16 Million 0.58%

% of portfolio

0.73%

Previous 0.8%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $7,820 - $8,598	17 Added 0.19%	8,898 $4.14 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $82,882 - $102,446	211 Added 2.43%	8,881 $4.16 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $859,002 - $939,890	2,107 Added 32.1%	8,670 $3.62 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $154,350 - $184,806	450 Added 7.36%	6,563 $2.67 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $475,819 - $509,981	1,407 Added 29.9%	6,113 $2.13 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $992,938 - $1.11 Million	3,158 Added 204.01%	4,706 $1.66 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $60,044 - $68,497	212 Added 15.87%	1,548 $487,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $15,431 - $17,359	54 Added 4.21%	1,336 $385,000
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $21,632 - $24,136	-79 Reduced 5.8%	1,282 $371,000
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $319,780 - $398,160	1,361 New	1,361 $384,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jt Stratford LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jt Stratford LLC with notifications on news.

Account